Does PDS Biotechnology Corporation (NASDAQ: PDSB) Offer Growth And Stability?

PDS Biotechnology Corporation (NASDAQ:PDSB) shares, rose in value on Thursday, April 04, with the stock price down by -3.94% to the previous day’s close as strong demand from buyers drove the stock to $3.54.

Actively observing the price movement in the recent trading, the stock is buoying the session at $3.68. The value of beta (5-year monthly) is 1.73. Referring to stock’s 52-week performance, its high was $10.27, and the low was $3.61. On the whole, PDSB has fluctuated by -39.05% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

With the market capitalization of PDS Biotechnology Corporation currently standing at about $129.66 million, investors are eagerly awaiting this quarter’s results, scheduled for May 13, 2024 – May 17, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.37, which is expected to increase to -$0.28 for fiscal year -$1.48 and then to about -$1.61 by fiscal year 2025. Data indicates that the EPS growth is expected to be -6.50% in 2025, while the next year’s EPS growth is forecast to be -8.80%.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that PDSB’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 50% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of PDSB currently trading nearly -24.41% and -31.90% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 29.20, while the 7-day volatility ratio is showing 11.66% which for the 30-day chart, stands at 8.92%. Furthermore, PDS Biotechnology Corporation (PDSB)’s beta value is 1.72, and its average true range (ATR) is 0.39.

A comparison of PDS Biotechnology Corporation (PDSB) with its peers suggests the former has fared considerably weaker in the market. PDSB showed an intraday change of -3.94% in today’s session so far, and over the past year, it shrunk by -41.67%%.

Data on historical trading for PDS Biotechnology Corporation (NASDAQ:PDSB) indicates that the trading volumes over the past 10 days have averaged 1.6 million and over the past 3 months, they’ve averaged 902.31K. According to company’s latest data on outstanding shares, there are 36.68 million shares outstanding.

Nearly 4.89% of PDS Biotechnology Corporation’s shares belong to company insiders and institutional investors own 22.45% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.51 million shares as on Mar 15, 2024, resulting in a short ratio of 5.52. According to the data, the short interest in PDS Biotechnology Corporation (PDSB) stood at 17.70% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 5.01 million. The stock has fallen by -28.87% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PDSB stock heading into the next quarter.